The PrEPWatch Resource Database offers a wide range of material on the status of PrEP as an option for biomedical HIV prevention around the world. Search this database to find step-by-step guidance for rolling out PrEP, summaries of the research to date on safety, efficacy and implementation, tools to assist planning and roll out, country updates on PrEP policy and access, and lessons learned from those efforts.
Showing results 1 - 10 of 64
What can modelling tell us about the scale-up of CAB for PrEP?
This factsheet summarises the results of mathematical modelling exercises of Cabotegravir (CAB) for PrEP rollout undertaken by researchers affiliated with the HIV Modelling Consortium. These results can help implementers and policymakers understand what to expect and guide early policy decisions to ensure CAB for PrEP is able to have maximum impact on reducing the HIV…
Research, Service Delivery, Testing
PrEP Product Awareness, Preferences, and Past Experiences among Transgender Women and Men Who Have Sex with Men in Asia and Australia: The PrEP APPEAL Study
This report provides an overview of PrEP Product Awareness, Preferences, and Past Experiences among Transgender Women and Men Who Have Sex with Men in Asia and Australia (PrEP APPEAL), a survey study in 16 countries and territories in Asia and Australia. The overall goal of PrEP APPEAL was to identify values and preferences about PrEP,…
Demand Creation/Marketing, Research, Service Delivery
Advocates’ Primer on Injectable Cabotegravir for PrEP
This document, designed for advocates, focuses on injectable cabotegravir for PrEP, outlining what’s known and what’s next for this emerging biomedical HIV prevention strategy. A summary slide deck with additional details can be found here.
Feasibility of Long Acting Injectable Cabotegravir PrEP Initiation and Administration by Community Health Workers and Early Aspects of the PrEP Injection Care Continuum in a Primary Care Center in Washington, D.C.
This poster presentation, delivered at IAS 2023 by the Whitman-Walker Institute, describes the integration of long acting injectable cabotegravir for PrEP, administered by community health workers, or non medically licensed staff, in a primary health clinic in Washington, D.C., USA.
Research, Service Delivery
Shaping and Coordinating the Implementation Science Agenda for Injectable Cabotegravir for PrEP: The role of the Biomedical Prevention Implementation Collaborative (BioPIC)
This article from JIAS describes the coordinated approach taken by the Biomedical Prevention Implementation Collaborative (BioPIC) to ensure questions regarding delivery of cabotegravir (CAB) for PrEP are addressed so that CAB can be introduced in low- and middle-income countries in timely, acceptable and effective ways.
Counterfactual Estimation of Efficacy against Placebo for Novel PrEP Agents Using External Trial Data: Example of injectable cabotegravir and oral PrEP in women
This article from JIAS uses estimated prevention efficacy against a counterfactual placebo to provide information on the use of cabotegravir for PrEP and oral PrEP compared to no intervention.
Integrated Study Dashboard
This dashboard, produced under the BioPIC project, reflects all currently known activities relating to implementation research, modelling, clinical research, and landscaping for new late stage biomedical HIV PrEP options, including cabotegravir for PrEP and the dapivirine vaginal ring. To update or add any activities missing from the dashboard, or if you have questions on using…
SCOPE Community E-meeting: Developments in PrEP implementation issues
The European AIDS Treatment Group, along with European and local organizations are coming together for a virtual meeting via Zoom e-meeting on Wednesday, June 7 at 6:00 to 7:30 AM ET (12:00 – 13:30 PM CET). This interactive e-meeting for community educators and advocates will provide an update on the latest developments and issues in…
Monitoring & Evaluation, Research
SCOPE Community E-meeting: Developments in the HIV and STIs biomedical prevention pipeline
The European AIDS Treatment Group, along with European and local organizations are coming together for a virtual meeting via Zoom e-meeting on Wednesday, May 24 at 6:00 to 7:30 AM ET (12:00 – 13:30 PM CET). This interactive e-meeting for community educators and advocates will provide an update on the latest developments in biomedical HIV…
Monitoring & Evaluation, Research
Deep Dive Review of Modelling Long Acting PrEP Meeting Summary
In March 2023, the Bill and Melinda Gates Foundation convened modellers looking into the impact, costs, and/or cost effectiveness of cabotegravir (CAB) for PrEP in low and middle income countries. This meeting summary provides an overview of 11 models as well as key insights emerging from the models and knowledge gaps.